Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) are two rare kidney diseases. They’re both driven by activity of the complement system, which is a ...

Also called C3G, this rare kidney disease often affects children and young adults, but it can happen at any age. It has major impact on a person’s health and life. C3G has two forms: dense deposit ...

Omeros stock catapulted Wednesday after Novo Nordisk agreed to pay up to $2.1 billion to license its experimental treatment.

ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that it will present initial Phase 1 clinical data for ADX ...

CPV-104 is the only recombinant Factor H in clinical development and has received EU Orphan Drug Designation for C3GEleva successfully completed ...

Anemia caused by the autoimmune disorder cold agglutin disease now has its first approved treatment, a Sanofi drug designed to block a pathway key to the progression of this condition. The FDA’s ...

() -Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.-based company's experimental drug, ...